An addition of medium-dose ATG to conditioning regimens favours the long-term survival of patients with allogeneic hematopoietic stem cell transplantation

Bingyi Wu, Chaoyan Song, Zhigang Lu, Kunyuan Guo, Yingzhi He, Sanfan Tu, Shaojuan Pan, Can Sun, Junyong Fang

Department of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

DOI: 10.4236/scd.2013.31004                

Abstract

Long-term survival of 116 leukemia/MDS patients received allo-SCT conditioned by a regimen with ATG-F or without ATG-F was analysed, together with the impact of ATG-F on the long-term survival, GVHD and disease relapse. Seventy patients received an ATG-F containing conditioning regimen FBCA, and 46 patients received a non-ATG-F FBC regimen. The FBCA regimen was associated with a 5-year survival of 65.4% in the complete HLA-matched group and 39.3% in the HLA-mismatched group. The difference between the two groups was significant (P = 0.012). For the FBC conditioning regimen, the 5-year overall survival of HLA-matched patients and the HLA-mismatched patients was 34.2% and 24.2% respectively (P = 0.216). The incidence of cGVHD was 32.9% and 83.6% in the FBCA and FBC condition regimen group respectively. Only 2.9% of the cases showed extensive cGVHD in the FBCA group while it was 69.4% in the FBC group (P = 0.00). Multivariate analysis indicated that relapse was related to the disease status and HLA typing, but unrelated to the conditioning regimens whether or not ATG-F was used (HR 0.54, P = 0.109). We conclude that the addition of ATG-F to conditioning regimen favours the longterm survival of allo-SCT.

Keywords

Hematopoietic Stem Cell Transplantation; Long-Term Survival; Anti-Human Lymphocyte Globulin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Greinix, H.T., Loidolt, H., Rabitsch, W., Schulenburg, A., Keil, F., Mitterbauer, M., Laczika, K., Lechner, K., Dieckmann, K., Fischer, G., J?ger, U., Rosenmayr, A., Kn?bl, P., Schwarzinger, I., H?cker, P., Mannhalter, C., Hinterberger, W., Haas, O.A., Fonatsch, C. and Kalhs, P. (2000) Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia. Annals of Hematology, 79, 206-213. doi:10.1007/s002770050580
[2]	Abou-Mourad, Y.R., Lau, B.C., Barnett, M.J., Forrest, D.L., Hogge, D.E., Nantel, S.H., Nevill, T.J., Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J., Toze, C.L. and Lavoie, J.C. (2010) Long-term outcome after allo-SCT: Close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplantation, 45, 295-302. doi:10.1038/bmt.2009.128
[3]	Fung, H.C., Stein, A., Slovak, M., O’donnell, M.R., Snyder, D.S., Cohen, S., Smith, D., Krishnan, A., Spielberger, R., Bhatia, R., Bhatia, S., Falk, P., Molina, A., Nademanee, A., Parker, P., Rodriguez, R., Rosenthal, J., Sweetman, R., Kogut, N., Sahebi, F., Popplewell, L., Vora, N., Somlo, G., Margolin, K., Chow, W., Smith, E. and Forman, S.J. (2003) A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome. Biology of Blood and Marrow Transplantation, 9, 766-771. doi:10.1016/j.bbmt.2003.08.004
[4]	Petersdorf, E.W. (2008) Optimal HLA matching in hematopoietic cell transplantation. Current Opinion in Immunology, 20, 588-593. doi:10.1016/j.coi.2008.06.014
[5]	Szydlo, R., Goldman, J.M., Klein, J.P., Gale, R.P., Ash, R.C., Bach, F.H., et al. (1997) Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. Journal of Clinical Oncology, 15, 1767-1777.
[6]	Hahn, T., McCarthy Jr., P.L., Zhang, M.J., Wang, D., Arora, M., Frangoul, H., et al. (2008) Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. Journal of Clinical Oncology, 26, 5728-5734. doi:10.1200/JCO.2008.17.6545 ,
[7]	Russell, J.A., Turner, A.R., Larratt, L., Chaudhry, A., Morris, D., Brown, C., Quinlan, D. and Stewart, D. (2007) Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biology of Blood and Marrow Transplantation, 13, 299-306. doi:10.1016/j.bbmt.2006.10.017
[8]	Nash, R.A., Antin, J.H., Karanes, C., Fay, J.W., Avalos, B.R., Yeager, A.M., et al. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood, 96, 2062-2068.
[9]	Grüllich, C., Ziegler, C. and Finke, J. (2009) Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistan. Biology of Blood and Marrow Transplantation, 15, 173-182. doi:10.1016/j.bbmt.2008.11.014
[10]	Remberger, M., Mattsson, J. and Ringd, N.O. (2001) Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatric Transplantation, 5, 285-292. doi:10.1034/j.1399-3046.2001.005004285.x
[11]	Finke, J., Schmoor, C., Lang, H., Potthoff, K. and Bertz, H. (2003) Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. Journal of Clinical Oncology, 21, 506-513. doi:10.1200/JCO.2003.03.129
[12]	Finke, J., Bethge, W.A., Schmoor, C., Ottinger, H.D., Stelljes, M., Zander, A.R., et al. (2011) Standard graftversus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. The Lancet Oncology, 10, 855-864. doi:10.1016/S1470-2045(09)70225-6
[13]	Mothy, M. and Gaugler, B. (2010) Advances in umbilical cord transplantation: The role of thymoglobulin/ATG in cord blood transplantation. Best Practice & Research Clinical Haematology, 23, 225-282. doi:10.1016/j.beha.2010.05.004
[14]	Soiffer, R.J., Lerademacher, J., Ho, V., Kan, F., Artz, A., Champlin, R.E., et al. (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stemcell transplantation for hematologic malignacies. Blood, 117, 6963-6970. doi:10.1182/blood-2011-01-332007
[15]	Kumar, A., Mhaskar, A.R., Reljic, T., Mhaskar, R.S., Kharfan-Dabaja, M.A., Anasetti, C., Mohty, M., Djulbegovic, B. (2012) Anti-thymocyte globulin for acutegraft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: A systematic review. Leukemia, 26, 582-588. doi:10.1038/leu.2011.349
[16]	Mohty, M., Labopin, M., Balere, M.L., Socie, G., Milpiedl, N., Tabrizi, R., et al. (2010) Antithymocyte globulins and chronic graft vs host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: A report from the Socie te Francaise de Greffe de Moelle et de. Therapie Cellulaire Leukemia, 24, 1867-1874. doi:10.1038/leu.2010.200
[17]	Podgorny, P.J., Ugarte-Torres, A., Liu, Y., Williamson, T.S., Russell, J.A. and Storek, J. (2010) High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biology of Blood and Marrow Transplantation, 16, 915-926. doi:10.1016/j.bbmt.2010.02.027
[18]	Devillier, R., Crocchiolo, R., Castagna, L., Fürst, S., El Cheikh, J., Faucher, C., Prebet, T., Etienne, A., Chabannon, C., Vey, N., Esterni, B. and Blaise, D. (2012) The increase from 2.5 to 5?mg/kg of rabbit anti-thymocyteglobulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplantation, 47, 639-645. doi:10.1038/bmt.2012.3
[19]	Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., et al. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. The New England Journal of Medicine, 314, 729-735. doi:10.1056/NEJM198603203141201
[20]	Meijer, E., Boland, G.J. and Verdonck, L.F. (2003) Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clinical Microbiology Reviews, 16, 647-657. doi:10.1128/CMR.16.4.647-657.2003
[21]	Wilson, D.T., Drew, R.H. and Perfect, J.R. (2009) Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: An update. Mycopathologia, 168, 313-327. doi:10.1007/s11046-009-9193-9
[22]	Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.-G., Beatty, P., Hows, J., et al. (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplantation, 15, 825-828.
[23]	Bacigalupo, A. (2007) Management of acute graft-versushost disease. British Journal of Haematology, 137, 87-98. doi:10.1111/j.1365-2141.2007.06533.x
[24]	Lee, S.J., Vogelsang, G. and Flowers, M.E.D. (2003) Chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 9, 215-233. doi:10.1053/bbmt.2003.50026
[25]	Wu, B., Guo, K., Song, C., Yang, D.A. and Li, D. (2000) Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versushost disease after non-T cell-depleted HLA-mismatched peripheral blood stem cell transplantation. Bone Marrow Transplantation, 26, 691-693. doi:10.1038/sj.bmt.1702563
[26]	Bacigalupo, A., Lamparelli, T., Barisione, G., Bruzzi, P., Guidi, S., Alessandrino, P.E., et al. (2006) Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Longterm follow-up of a randomized trial in patients undergoing unrelated donor ransplantation. Biology of Blood and Marrow Transplantation, 12, 560-565. doi:10.1016/j.bbmt.2005.12.034
[27]	Kumar, A., Mhaskar, A.R., Reljic, T., Mhaskar, R.S., Kharfan-Dabaja, M.A., Anasetti, C., Mohty, M. and Djulbegovic, B. (2012) Antithymocyte globulin for acutegraft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: A systematic review. Leukemia, 26, 582-588. doi:10.1038/leu.2011.349
[28]	Kim, H.J., Min, W.S., Cho, B.S., Eom, K.S., Kim, Y.J., Min, C.K., Lee, S., Cho, S.G., Jin, J.Y., Lee, J.W. and Kim, C.C. (2009) Successful prevention of acute graftversus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biology of Blood and Marrow Transplantation, 15, 704-717. doi:10.1016/j.bbmt.2009.02.010
[29]	Mohty, M., Labopin, M., Balere, M.L., Socie, G., Milpied, N., Tabrizi, R., et al. (2010) Antithymocyte globulins and chronic graft vs host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: A report from the Socie te Francaise de Greffe de Moelle et de. Therapie Cellulaire Leukemia, 24, 1867-1874. doi:10.1038/leu.2010.200
[30]	Bredeson, C.N., Zhang, M.J., Agovi, M.A., Bacigalupo, A., Bahlis, N.J., Ballen, K., Brown, C., Chaudhry, M.A., Horowitz, M.M., Kurian, S., Quinlan, D., Muehlenbien, C.E., Russell, J.A., Savoie, L., Rizzo, J.D. and Stewart, D.A. (2008) Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: A matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biology of Blood and Marrow Transplantation, 14, 993-1003. doi:10.1016/j.bbmt.2008.06.009